←
Chul Kim4,113 posts
Chul Kim avatar

Chul Kim

@chulkimMD

Director of Thoracic Oncology at Georgetown University @Lombardicancer / Lung Cancer, Thymic Tumors, Phase I / #Editor @ClinicalLung / Secretary of ITMIG

◷ Joined February 2017▧ 793 Photos and videos
The Medical Educator Consortium avatar
⟳ Chul Kim retweeted
The Medical Educator Consortium@mecmededucation·16h

Last chance to register for MaTOS Lung Edition 2026! Join leading experts in lung cancer for an exceptional educational experience focused on the latest clinical insights, emerging evidence, and evolving strategies in thoracic oncology. Learn directly from renowned faculty, exchange perspectives with the oncology community, and stay current on the advances shaping lung cancer care. 📅 November 19–22, 2026 📍 The Ritz-Carlton, Half Moon Bay, CA Industry partners: There’s still time to connect with the thoracic oncology community. Limited sponsorship and exhibit opportunities remain. Contact us to reserve your space. Registration is closing soon. Secure your spot today at matos-lung.com #MaTOS #MaTOSLung #LungCancer #ThoracicOncology #OncologyEducation #MedicalEducation #ClinicalOncology #CancerCare #OncologyConference #RegisterNow @DasMillie11 @delvysra @DDoroshow @lungoncdoc @BalazsHalmosMD @WadeIams @ReckampK @yyelamin @JustinGainor @NaglaAKarimMD @LauraAlderMD @LindaMThoracic @BenCreelan @triparnasen @DCarboneMD @luisraezmd @md_hsu @Joshua_Reuss @lexiuning @Latinamd @drshieldsmd @SCLCSMASHERS @CoreyLanger @EddieSantosMD @collin_blakely @ShirishGadgeel @christine_lovly @chulkimMD @MattGubensMD @hosseinborghaei @StephenVLiu @iyengarpuneeth @ChaftJamie @maryjofidlermd @BRicciutiMD @MNagasaka

0:35
Chul Kim avatar
Chul Kim@chulkimMD·19h

#Neladalkib approved for previously treated ALK+ advanced NSCLC. ALKOVE-1: - ORR: 49% after alectinib (n=67) and 32% after ≥2 ALK TKIs + platinum (n=155) - DOR ≥12 mo: 52% and 51% of responders, respectively Important advance and option in ALK fusion NSCLC!

FDA grants accelerated approval to neladalkib (NVL-655) for advanced ALK positive NSCLC with prior TKI therapy. Based on ALKOVE-1 study - post alectinib RR 49%, more than half of responses ongoing at a year. Favorable tox profile. New best in class? fda.gov/drugs/cancer-approva…

Andre Moreira avatar
⟳ Chul Kim retweeted
Andre Moreira@AndreMo77438628·Nov 14

I am happy to have been a member of the program committee to another successful meeting for ITMIG 2026 Bye-bye São Paulo!!

Post attachment
Chul Kim avatar
Chul Kim@chulkimMD·Nov 14

Updated results from the phase II PECATI study of lenvatinib + pembrolizumab in previously treated B3 thymoma/thymic carcinoma (n=43): • ORR 25.6% • mPFS 22.1 months (!) • mOS 40.2 months Simultaneous publication @JTOonline! Congrats to authors #ITMIG2026 @JordiRemon

Post attachmentPost attachmentPost attachmentPost attachment
Chul Kim avatar
Chul Kim@chulkimMD·Nov 14

This will certainly be a memorable ITMIG meeting for me. Heartfelt thanks to all our faculty and attendees who traveled from near and far to discuss and share ideas on advancing the field and improving care for patients with thymic malignancies. So grateful. #ITMIG2026 @Itmig_society

Post attachment
Chul Kim avatar
Chul Kim@chulkimMD·Nov 14

My colleague Dr. Edward Chan from @MedStarGUH presents a challenging thymic carcinoma case at #ITMIG2026, raising several important questions about neoadjuvant chemotherapy + ramucirumab for borderline resectable disease, robotic surgery, and MRD.

Post attachment
Chul Kim avatar
Chul Kim@chulkimMD·Nov 14

The thymic tumor board dream team! If I had a challenging thymic tumor case to present, this is exactly the group of experts I’d want in the room. #ITMIG2026

Post attachment
Chul Kim avatar
Chul Kim@chulkimMD·Nov 14

Great talk by Dr. James Huang from MSKCC on the impact of neoadjuvant treatment on resectability and surgical outcomes. Caring for patients with cancer—especially rare tumors like TETs—takes a village. Multidisciplinary collaboration is essential. #ITMIG2026

Post attachmentPost attachment
Chul Kim avatar
Chul Kim@chulkimMD·Nov 14

Insightful keynote by Dr. @HwakeleeMD on neoadjuvant/perioperative systemic therapy in TETs. Agents being developed for advanced disease may expand options in this setting, but careful trial design is needed to balance potential benefit with toxicity. #ITMIG2026

Post attachmentPost attachment
Chul Kim avatar
Chul Kim@chulkimMD·Nov 14

Dr. Rohan Maniar elegantly outlined the opportunities and challenges of drug development for rare tumors like TETs. We need to learn from every patient and keep bringing novel agents to the clinic, with basic/translational research advancing alongside clinical trials. #ITMIG2026

Post attachmentPost attachment